Company intelligence / Profile preview

Molecular Express

Rancho Dominguez, California, United Statesmolecularexpress.com ↗

Ownership: Private
Development stage: Other

Overview

Molecular Express has developed advanced formulation services and the proprietary Molecular GPS™ platform for targeted drug delivery. The company has received SBIR funding from NIAID to develop a universal influenza vaccine in collaboration with Tulane University and UC Davis. No published clinical results are available; the program appears preclinical or early stage[6].

Therapeutic areas: Infectious DiseasesOther
Modalities: VaccineProteinSmall molecule
Industry: Biotech

Drug pipeline

4 assets

liposomal disintegrin

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Over 50 academic institutionsNIH/NIAIDTulane UniversityUC Davis California National Primate Research Center

Beyond the preview

Go deeper on Molecular Express.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Express.

Explore the full profile